{"id":790344,"date":"2024-11-25T08:03:00","date_gmt":"2024-11-25T13:03:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/"},"modified":"2024-11-25T08:03:00","modified_gmt":"2024-11-25T13:03:00","slug":"aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/","title":{"rendered":"AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders<\/b><\/p>\n<p class=\"bwalignc\"><i>Highlights How Positive Data in AIM\u2019s Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commercialization Opportunities in High-Value Indications Including Pancreatic Cancer<\/i><\/p>\n<p class=\"bwalignc\"><i>Warns Shareholders of Its Belief that the Activist Group and Its Nominees Have a Self-Interested Agenda and Could Put AIM\u2019s Clinical Progress at Risk<\/i><\/p>\n<p class=\"bwalignc\"><i>Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates and Discarding Any Proxy Materials from the Activist Group<\/i><\/p>\n<p class=\"bwalignc\"><i>Shareholders Can View and Download the Presentation <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmunotech.s3.us-west-1.amazonaws.com%2FAIM%2BInvestor%2BPresentation%2B%28November%2B2024%29.pdf&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=Here&amp;index=1&amp;md5=aebd9987f2d8525d889b11917beb3e81\">Here<\/a><\/i><\/p>\n<p>OCALA, Fla.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAIM ImmunoTech Inc. (NYSE American: AIM) (\u201cAIM\u201d or the \u201cCompany\u201d) today issued a <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmunotech.s3.us-west-1.amazonaws.com%2FAIM%2BInvestor%2BPresentation%2B%28November%2B2024%29.pdf&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=presentation&amp;index=2&amp;md5=f3ad08194b4528269f1b5432d10f7266\">presentation<\/a> in connection with its upcoming 2024 Annual Meeting of Stockholders the (\u201cAnnual Meeting\u201d), presently scheduled for December 17, 2024.<\/p>\n<p>\nHighlights of the presentation include the following:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nAIM is executing on its strategy to create <b>long-term value for patients and shareholders<\/b> by driving clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space.<\/p>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nAIM\u2019s clinical pipeline has significant momentum and is laying the <b>groundwork for commercialization opportunities<\/b> by delivering exciting data across clinical trials, including in two ongoing studies with AstraZeneca and Merck. These commercialization opportunities are what can drive substantial value creation.<\/p>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nIf elected, the Activist Group intends to seek over<b> $5 million <\/b>from AIM to pay for its previous takeover attempts and litigation against the Company that the Activist Group lost, in addition to any expenses incurred in connection with its solicitation for this year\u2019s Annual Meeting. The Activist Group disclosed that it does not<i \/>intend to put this personal reimbursement to a shareholder vote.<\/p>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nDespite AIM\u2019s best attempts at a constructive settlement that would put two of the Activist Group\u2019s nominees on the Board, the Activist Group has continued to insist it receive <b>upwards of $8 million<\/b> to make all litigants whole in connection with certain litigation as part of any resolution \u2013 this <b>represents more than 50% of AIM\u2019s current market capitalization<\/b>.<\/p>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nThe Activist Group has indicated it would likely appoint Robert Chioini as interim CEO while the Board runs a succession process should its nominees gain control of the Board. Mr. Chioini was fired as CEO of Rockwell Medical in 2018 because of his<i> \u201c<b>sustained mismanagemen<\/b><b>t<\/b>\u201d <\/i>of the company and <i>\u201c<b>blatant disregard for shareholder concerns<\/b>,\u201d<\/i> according to a Rockwell Medical spokesperson.<sup>1<\/sup> Following his termination, Mr. Chioini<i> \u201crefuse[d] to accept the decision\u201d<\/i> and, without authorization, filed a Current Report on Form 8-K on the company\u2019s behalf <i>\u201cmaking various assertions regarding the five independent directors who voted in favor of Mr. Chioini\u2019s removal.\u201d<\/i><sup>2<\/sup><i \/>This behavior indicates, in our view, that Mr. Chioini is unfit to serve as a public company director \u2013 let alone CEO.<\/p>\n<\/li>\n<\/ul>\n<p>\nAIM encourages shareholders to review its presentation and vote <b>FOR<\/b> the Board\u2019s incumbent candidates \u2013 <b>Stewart L. Appelrouth<\/b>, <b>Nancy K. Bryan<\/b>, <b>Thomas K. Equels<\/b> and <b>Dr. William M. Mitchell<\/b> \u2013 on the <b><span class=\"bwuline\">WHITE<\/span><\/b> universal proxy card.<\/p>\n<p>\nFor more information on how to vote, visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.SafeguardAIM.com&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=www.SafeguardAIM.com&amp;index=3&amp;md5=ff07f34fd9a0379e8bc3ebebd80b0ad0\">www.SafeguardAIM.com<\/a>.<\/p>\n<p class=\"bwalignc\"><b>WE URGE YOU TO COMPLETE, SIGN, DATE AND RETURN THE <span class=\"bwuline\">WHITE<\/span> UNIVERSAL PROXY CARD AND MAIL IT PROMPTLY IN THE POSTAGE-PAID ENVELOPE PROVIDED, OR VOTE BY INTERNET AS INSTRUCTED ON THE <span class=\"bwuline\">WHITE<\/span> UNIVERSAL PROXY CARD, WHETHER OR NOT YOU PLAN TO VIRTUALLY ATTEND THE ANNUAL MEETING.<\/b><\/p>\n<p class=\"bwalignc\"><b>THE BOARD RECOMMENDS A VOTE \u201cFOR\u201d ALL OF OUR BOARD\u2019S CANDIDATES (STEWART L. APPELROUTH, NANCY K. BRYAN, THOMAS K. EQUELS AND DR. WILLIAM M. MITCHELL) ON PROPOSAL 1 USING THE <span class=\"bwuline\">WHITE<\/span> UNIVERSAL PROXY CARD.<\/b><\/p>\n<p><b>About AIM ImmunoTech Inc.<\/b><\/p>\n<p>\nAIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company\u2019s lead product is a first-in-class investigational drug called Ampligen<sup>\u00ae<\/sup> (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.<\/p>\n<p>\nFor more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DNJE1OVmM3vXX32UkYGXxM6a6gkfQ_2DnYLGx5Klimcg0SIUEXl6aHRMSXtvH1CLTDWpH3rTZCiAufpi5t6p-9p0EjO4NkMNsbEmaTpDEswzNvszJH-aM8EOVRVV888nSbRAC2vgyABZdN43GQxbKWBWzq50NJCOKM_txPvOidUGSpZiA6wkCZ9XafYPMf374-f3xMdS5d6mvfaEOh-SJLIKjWpDnDC4MU6UbdbumhiM%3D&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=aimimmuno.com&amp;index=4&amp;md5=c9f51ac3544d73f16dbec04b6d74f748\">aimimmuno.com<\/a> and connect with the Company on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D92BdXKffHdlioqhz-03Fs1SCxSuJ_YoMC7zzeRUzUmKpf7AaDkBpYBTNmSb7rglz-sAOfhSiDQnjcDs7oVHDxRh8XwYe4c-pmYVskUuuh8bvCHDBFGX4xLNz1zK4hU7V6GLIwLCNHTpTc3UrFO1v2vYwW81LULNmHnyAioz-3x4z48aJsAJoIQ8tFBHNuatL8y9ibmHX8n4XrDgC1-b7mA%3D%3D&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=X&amp;index=5&amp;md5=8a5a0927777d8961a64f04c76bcf714b\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DsH78EHx_UKrXcfI2LUu9Z-lJSSOS6QZWbFZ_oXe2paNrGUii0hZrZS-O8LpzT9xas82flUWriJU1CELIbJRK3auVrVaEDkTliYmOtiiS1roLBVcUKuFc-VDV3F9CDOzZtpr5OP-EhbFK6rWaduz5-fjevnRRIXmlvFUqnlpPBQjjsV2btrpz-PCrlg5pZboGQ-kTvRf26jHEl590OiKDSQJFO18V8Jv64H91CHtkRYqC2k-setqZttauwo7FW8mY&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=b346409dacbc00b33d0fc901c6c21773\">LinkedIn<\/a>, and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DJeXN46_2i1JvodZ_6kBxk9GunKEzpFGqa2Zmmrlzfr4Raz091cyw-p8SHz23j3lH6K5xQJYu-rKrBzzt7EpdtatCcPFQhMr5aS_RpmlQP2HbCicT2yIIM0Ye7C_X2GrDyMo2HtaxnWuXkNHO4tixq669IbfdjHIGzxPmlgv2n2HYlb4VgXnlnYvcMdFgr2LS-P21zmT51kPJv3oeCw7PI4dx2Oaf5iH_8SeuZPb3MuZi95OBx6XpmsSUQjgSPirK&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=Facebook&amp;index=7&amp;md5=fe4bce8874552a4f7f3ea4d5e6e7a582\">Facebook<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the \u201cPSLRA\u201d). Words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccontinue,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201cupcoming\u201d and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date does not guarantee that Ampligen will be approved as a treatment or therapy for any diseases or conditions. The Company urges investors to consider specifically the various risk factors identified in its most recent Annual Report on Form 10-K, and any risk factors or cautionary statements included in any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.<\/p>\n<p><b>Important Additional Information<\/b><\/p>\n<p>\nThe Company, its directors and executive officers, Peter W. Rodino, III and Robert Dickey, IV, are deemed to be \u201cparticipants\u201d (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company\u2019s stockholders in connection with the Annual Meeting. The Company filed its definitive proxy statement (the \u201cDefinitive Proxy Statement\u201d) and a <b>WHITE <\/b>universal proxy card with the SEC on November 4, 2024 in connection with such solicitation of proxies from the Company\u2019s stockholders. <b>STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH DEFINITIVE PROXY STATEMENT, ACCOMPANYING WHITE UNIVERSAL PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING.<\/b> The Definitive Proxy Statement contains information regarding the identity of the participants, and their direct and indirect interests, by security holdings or otherwise, in the Company\u2019s securities and can be found in the section titled \u201cPrincipal Stockholders\u201d of the Definitive Proxy Statement and available <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F946644%2F000149315224043423%2Fformdefc14a.htm%23%3A%7E%3Atext%3Dour%2520common%2520stock.-%2CPRINCIPAL%2520STOCKHOLDERS%2C-The%2520following%2520table&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=here&amp;index=8&amp;md5=cc412efa5d8516f2121757868b62fd60\">here<\/a>. Information regarding subsequent changes to their holdings of the Company\u2019s securities can be found in the SEC filings on Forms 3, 4, and 5, which are available on the Company\u2019s website available <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmuno.com%2Fsec-filings%2F&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=here&amp;index=9&amp;md5=d79f27ddac3a2a1291a5d5e1ea2ecb21\">here<\/a> or through the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=b4e87864f2afecf43a7a26b03f21e6a0\">www.sec.gov<\/a>. Stockholders will be able to obtain the Definitive Proxy Statement, any amendments or supplements thereto and other documents filed by the Company with the SEC at no charge at the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=11&amp;md5=01f3a51513f3ddd79fa5c827a2dbdbf8\">www.sec.gov<\/a>. Copies will also be available at no charge at the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmuno.com%2Fsec-filings%2F&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=https%3A%2F%2Faimimmuno.com%2Fsec-filings%2F&amp;index=12&amp;md5=513d45778f4b3a2a73c8615c725f9439\">https:\/\/aimimmuno.com\/sec-filings\/<\/a>.<\/p>\n<p><sup>1<\/sup><i>See <\/i>Modern Healthcare, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.modernhealthcare.com%2Farticle%2F20180618%2FNEWS%2F180619912%2Fformer-pharma-executives-sue-over-firings&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=Former+pharma+executives+sue+over+firings&amp;index=13&amp;md5=45e000406350e2c9de5a556f1ddfc282\">Former pharma executives sue over firings<\/a> (June 18, 2018).<br \/>\n<br \/><sup>2<\/sup><i>See <\/i>Press Release issued by Rockwell Medical on May 24, 2018, available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Frockwell-medical-issues-statement-300654699.html&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Frockwell-medical-issues-statement-300654699.html&amp;index=14&amp;md5=c8867da232dbe61925ec3ee7b41a69fe\">https:\/\/www.prnewswire.com\/news-releases\/rockwell-medical-issues-statement-300654699.html<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241125176144r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20241125176144\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20241125176144\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>JTC Team, LLC<br \/>\n<br \/>Jenene Thomas<br \/>\n<br \/>908-824-0775<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:AIM@jtcir.com\">AIM@jtcir.com<br \/>\n<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Longacre Square Partners<br \/>\n<br \/>Joe Germani \/ Miller Winston<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:AIM@longacresquare.com\">AIM@longacresquare.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Florida<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Finance Oncology Health Professional Services Clinical Trials Other Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders Highlights How Positive Data in AIM\u2019s Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commercialization Opportunities in High-Value Indications Including Pancreatic Cancer Warns Shareholders of Its Belief that the Activist Group and Its Nominees Have a Self-Interested Agenda and Could Put AIM\u2019s Clinical Progress at Risk Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates and Discarding Any Proxy Materials from the Activist Group Shareholders Can View and Download the Presentation Here OCALA, Fla.&#8211;(BUSINESS WIRE)&#8211; AIM ImmunoTech Inc. (NYSE American: AIM) (\u201cAIM\u201d or the \u201cCompany\u201d) today &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-790344","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders Highlights How Positive Data in AIM\u2019s Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commercialization Opportunities in High-Value Indications Including Pancreatic Cancer Warns Shareholders of Its Belief that the Activist Group and Its Nominees Have a Self-Interested Agenda and Could Put AIM\u2019s Clinical Progress at Risk Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates and Discarding Any Proxy Materials from the Activist Group Shareholders Can View and Download the Presentation Here OCALA, Fla.&#8211;(BUSINESS WIRE)&#8211; AIM ImmunoTech Inc. (NYSE American: AIM) (\u201cAIM\u201d or the \u201cCompany\u201d) today &hellip; Continue reading &quot;AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-25T13:03:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241125176144r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders\",\"datePublished\":\"2024-11-25T13:03:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\\\/\"},\"wordCount\":1284,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241125176144r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\\\/\",\"name\":\"AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241125176144r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2024-11-25T13:03:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241125176144r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241125176144r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/","og_locale":"en_US","og_type":"article","og_title":"AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders - Market Newsdesk","og_description":"AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders Highlights How Positive Data in AIM\u2019s Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commercialization Opportunities in High-Value Indications Including Pancreatic Cancer Warns Shareholders of Its Belief that the Activist Group and Its Nominees Have a Self-Interested Agenda and Could Put AIM\u2019s Clinical Progress at Risk Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates and Discarding Any Proxy Materials from the Activist Group Shareholders Can View and Download the Presentation Here OCALA, Fla.&#8211;(BUSINESS WIRE)&#8211; AIM ImmunoTech Inc. (NYSE American: AIM) (\u201cAIM\u201d or the \u201cCompany\u201d) today &hellip; Continue reading \"AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/","og_site_name":"Market Newsdesk","article_published_time":"2024-11-25T13:03:00+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241125176144r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders","datePublished":"2024-11-25T13:03:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/"},"wordCount":1284,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241125176144r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/","name":"AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241125176144r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2024-11-25T13:03:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241125176144r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241125176144r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/790344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=790344"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/790344\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=790344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=790344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=790344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}